keyword
https://read.qxmd.com/read/38628758/epigenetic-regulation-of-foxi2-promotes-clear-cell-renal-cell-carcinoma-progression
#1
JOURNAL ARTICLE
Shuai Zhou, Cong Cheng, Yi Xiang Liao, Li Wang, Jin Min Zeng, Fang Fang Zhou, Xiu Qin Zhang, Tao Yang
In recent decades, substantial advancements in epigenetics have unveiled a profound understanding of its mechanisms in tumorigenesis and have offered promising strategies for epigenetic therapy in cancer patients. In our study, through bioinformatics analysis, we discovered a significant downregulation and hypermethylation of FOXI2 in clear cell renal cell carcinoma (ccRCC), while the expression in chromophobe cell carcinoma (chRCC) exhibited the opposite trend. Moreover, we established a strong correlation between FOXI2 expression levels and the prognosis of ccRCC...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38628557/impressive-and-prolonged-response-with-lenvatinib-in-a-highly-pretreated-patient-with-metastatic-clear-cell-renal-cancer-a-case-report
#2
Sara Demurtas, Mara Frascaroli, Federico Sottotetti, Alessandro Rametta, Giuseppe Procopio, Laura Deborah Locati
Clear cell renal carcinoma (ccRCC) can occur in young people and could be associated with an aggressive behavior. While for the first-line treatment in metastatic disease, there is an agreement to rely on an immunotherapy (IO)-based combination regimen, no standard second-line regimens exist. Generally, tyrosine kinase inhibitors (TKIs) are employed, even in sequence, although no trials have demonstrated yet the best succession. Herein, we present the case of a 39-year-old male, with a very aggressive ccRCC with somatic VHL mutation and distant metastases at diagnosis...
2024: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/38618956/vhl-loss-reprograms-the-immune-landscape-to-promote-an-inflammatory-myeloid-microenvironment-in-renal-tumorigenesis
#3
JOURNAL ARTICLE
Melissa M Wolf, Matthew Z Madden, Emily N Arner, Jackie E Bader, Xiang Ye, Logan Vlach, Megan L Tigue, Madelyn D Landis, Patrick B Jonker, Zaid Hatem, KayLee K Steiner, Dakim K Gaines, Bradley I Reinfeld, Emma S Hathaway, Fuxue Xin, M Noor Tantawy, Scott M Haake, Eric Jonasch, Alexander Muir, Vivian L Weiss, Kathryn E Beckermann, W Kimryn Rathmell, Jeffrey C Rathmell
Clear cell renal cell carcinoma (ccRCC) is characterized by dysregulated hypoxia signaling and a tumor microenvironment (TME) highly enriched in myeloid and lymphoid cells. Loss of the von Hippel Lindau (VHL) gene is a critical early event in ccRCC pathogenesis and promotes stabilization of HIF. Whether VHL loss in cancer cells affects immune cells in the TME remains unclear. Using Vhl WT and Vhl-KO in vivo murine kidney cancer Renca models, we found that Vhl-KO tumors were more infiltrated by immune cells...
April 15, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38618953/vhl-governs-m6a-modification-and-pik3r3-mrna-stability-in-clear-cell-renal-cell-carcinomas
#4
JOURNAL ARTICLE
Hyemin Lee, Li Zhuang, Boyi Gan
N6-Methyladenosine (m6A), a prevalent posttranscriptional modification, plays an important role in cancer progression. Clear cell renal cell carcinoma (ccRCC) is chiefly associated with the loss of the von Hippel-Lindau (VHL) gene, encoding a component of the E3 ubiquitin ligase complex. In this issue of the JCI, Zhang and colleagues unveiled a function of VHL beyond its canonical role as an E3 ubiquitin ligase in regulating hypoxia-inducible factors (HIFs). It also governed m6A modification by orchestrating the assembly of m6A writer proteins METTL3 and METTL14, thereby stabilizing PIK3R3 mRNA...
April 15, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38618952/von-hippel-lindau-tumor-suppressor-controls-m6a-dependent-gene-expression-in-renal-tumorigenesis
#5
JOURNAL ARTICLE
Cheng Zhang, Miaomiao Yu, Austin J Hepperla, Zhao Zhang, Rishi Raj, Hua Zhong, Jin Zhou, Lianxin Hu, Jun Fang, Hongyi Liu, Qian Liang, Liwei Jia, Chengheng Liao, Sichuan Xi, Jeremy M Simon, Kexin Xu, Zhijie Liu, Yunsun Nam, Payal Kapur, Qing Zhang
N6-Methyladenosine (m6A) is the most abundant posttranscriptional modification, and its contribution to cancer evolution has recently been appreciated. Renal cancer is the most common adult genitourinary cancer, approximately 85% of which is accounted for by the clear cell renal cell carcinoma (ccRCC) subtype characterized by VHL loss. However, it is unclear whether VHL loss in ccRCC affects m6A patterns. In this study, we demonstrate that VHL binds and promotes METTL3/METTL14 complex formation while VHL depletion suppresses m6A modification, which is distinctive from its canonical E3 ligase role...
April 15, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38617927/characterization-of-a-g2m-checkpoint-related-gene-model-and-subtypes-associated-with-immunotherapy-response-for-clear-cell-renal-cell-carcinoma
#6
JOURNAL ARTICLE
Zhenwei Wang, Zongtai Zheng, Bangqi Wang, Changxin Zhan, Xuefeng Yuan, Xiaoqi Lin, Qifan Xin, Zhihui Zhong, Xiaofu Qiu
Clear cell renal cell carcinoma (ccRCC) presents challenges in early diagnosis and effective treatment. In this study, we aimed to establish a prognostic model based on G2M checkpoint-related genes and identify associated clusters in ccRCC through clinical bioinformatic analysis and experimental validation. Utilizing a single-cell RNA dataset (GSE159115) and bulk-sequencing data from The Cancer Genome Atlas (TCGA) database, we analyzed the G2M checkpoint pathway in ccRCC. Differential expression analysis identified 45 genes associated with the G2M checkpoint, leading to the construction of a predictive model with four key genes (E2F2, GTSE1, RAD54L, and UBE2C)...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38615487/nlr-outperforms-low-hemoglobin-and-high-platelet-count-as-predictive-and-prognostic-biomarker-in-metastatic-renal-cell-carcinoma-treated-with-immune-checkpoint-inhibitors
#7
JOURNAL ARTICLE
Matthew Young, Jose C Tapia, Bernadett Szabados, Agne Jovaisaite, Francesca Jackson-Spence, Elizabeth Nally, Thomas Powles
BACKGROUND: Reliable biomarkers in renal cell carcinoma (RCC) remain elusive. While several markers have been shown to be associated with prognosis, and may aid in risk assessment, predictive biomarkers of response to immune checkpoint inhibitors (ICIs) have not been established. Previous studies have shown that a high pretreatment neutrophil-lymphocyte ratio (NLR) is a negative prognostic factor in RCC. However, a clinically useful cut-off for the predictive and prognostic value of NLR has not been well defined...
March 8, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38614981/psat1-enhances-the-efficacy-of-the-prognosis-estimation-nomogram-model-in-stage-based-clear-cell-renal-cell-carcinoma
#8
JOURNAL ARTICLE
Jun Wang, Xiaoming He, Yuanyuan Mi, Yong Q Chen, Jie Li, Rong Wang
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is associated with a high prevalence of cancer-related deaths. The survival rates of patients are significantly lower in late-stage ccRCC than in early-stage ccRCC, due to the spread and metastasis of late-stage ccRCC, surgery has not reached the goal of radical cure, and the effect of traditional radiotherapy and chemotherapy is poor. Thus, it is crucial to accurately assess the prognosis and provide personalized treatment at an early stage in ccRCC...
April 13, 2024: BMC Cancer
https://read.qxmd.com/read/38612943/boosting-clear-cell-renal-carcinoma-specific-drug-discovery-using-a-deep-learning-algorithm-and-single-cell-analysis
#9
JOURNAL ARTICLE
Yishu Wang, Xiaomin Chen, Ningjun Tang, Mengyao Guo, Dongmei Ai
Clear cell renal carcinoma (ccRCC), the most common subtype of renal cell carcinoma, has the high heterogeneity of a highly complex tumor microenvironment. Existing clinical intervention strategies, such as target therapy and immunotherapy, have failed to achieve good therapeutic effects. In this article, single-cell transcriptome sequencing (scRNA-seq) data from six patients downloaded from the GEO database were adopted to describe the tumor microenvironment (TME) of ccRCC, including its T cells, tumor-associated macrophages (TAMs), endothelial cells (ECs), and cancer-associated fibroblasts (CAFs)...
April 8, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612906/wide-targeted-semi-quantitative-analysis-of-acidic-glycosphingolipids-in-cell-lines-and-urine-to-develop-potential-screening-biomarkers-for-renal-cell-carcinoma
#10
JOURNAL ARTICLE
Masamitsu Maekawa, Tomonori Sato, Chika Kanno, Izumi Sakamoto, Yoshihide Kawasaki, Akihiro Ito, Nariyasu Mano
Glycosphingolipids (GSLs), mainly located in the cell membrane, play various roles in cancer cell function. GSLs have potential as renal cell carcinoma (RCC) biomarkers; however, their analysis in body fluids is challenging because of the complexity of numerous glycans and ceramides. Therefore, we applied wide-targeted lipidomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with selected reaction monitoring (SRM) based on theoretical mass to perform a comprehensive measurement of GSLs and evaluate their potency as urinary biomarkers...
April 7, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612724/association-between-pd-l1-expression-and-the-prognosis-and-clinicopathologic-features-of-non-clear-cell-renal-cell-carcinoma
#11
JOURNAL ARTICLE
Magdalena Chrabańska, Nikola Szweda-Gandor, Magdalena Rynkiewicz, Dominik Hraboš, Bogna Drozdzowska
PD-L1 is one of the two programmed cell death 1 (PD-1) ligands and a part of an immune checkpoint system (PD-1/PD-L1) with widespread clinical application. The aim of this study was to investigate PD-L1 expression and its association with clinicopathological and prognostic significance in non-clear cell renal cell carcinoma (non-ccRCC) patients. A total of 41 papillary (pRCC) and 20 chromophobe (chRCC) RCC tumors were examined for PD-L1 expression by immunohistochemistry in the cancer cells and tumor-infiltrating mononuclear cells (TIMCs)...
March 31, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38610951/ruvbl1-in-clear-cell-renal-cell-carcinoma-unraveling-prognostic-significance-and-correlation-with-hif1a
#12
JOURNAL ARTICLE
Justyna Durślewicz, Aleksandra Maria Wybierała, Sara Szczepanek, Paulina Antosik, Damian Jaworski, Dariusz Grzanka
This study investigates the roles of RUVBL1 and HIF1A in ccRCC development and explores their clinical significance as prognostic biomarkers. mRNA and protein expressions were analyzed using TCGA data and an institutional tissue cohort, respectively. Correlations with clinicopathological parameters and patient outcomes were assessed. TCGA data revealed significantly elevated RUVBL1 mRNA expression in ccRCC tissues, associated with advanced histological grade, T stage, lymph node metastasis, and clinical stage...
March 25, 2024: Cancers
https://read.qxmd.com/read/38610686/the-pancreas-as-a-target-of-metastasis-from-renal-cell-carcinoma-is-surgery-feasible-and-safe-a-single-center-experience-in-a-high-volume-and-certified-pancreatic-surgery-center-in-germany
#13
JOURNAL ARTICLE
Sara Al-Madhi, Sara Acciuffi, Frank Meyer, Maximilian Dölling, Asmus Beythien, Mihailo Andric, Mirhasan Rahimli, Roland S Croner, Aristotelis Perrakis
Background : Secondary malignant tumors of the pancreas are rare, representing 2-5% of all pancreatic malignancies. Nevertheless, the pancreas is one of the target organs in cases of metastatic clear cell renal cell carcinoma (CCRCC). Additionally, recurrent metastasis may occur. Surgical resection remains the best and prognostically most favorable therapeutic option in cases of solitary pancreatic metastasis. Aim: To review retrospectively the clinical tumor registry of the University Hospital of Magdeburg, Germany, for this rare entity, performing a clinical systematic single-center observational study (design)...
March 26, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38607586/dual-loss-of-pbrm1-and-rad51-identifies-hyper-sensitive-subset-patients-to-immunotherapy-in-clear-cell-renal-cell-carcinoma
#14
JOURNAL ARTICLE
Ziyang Xu, Wenbin Jiang, Li Liu, Youqi Qiu, Jiahao Wang, Siyuan Dai, Jianming Guo, Jiejie Xu
BACKGROUND: Homologous recombination deficiency (HRD), though largely uncharacterized in clear cell renal cell carcinoma (ccRCC), was found associated with RAD51 loss of expression. PBRM1 is the second most common mutated genes in ccRCC. Here, we introduce a HRD function-based PBRM1-RAD51 ccRCC classification endowed with diverse immune checkpoint blockade (ICB) responses. METHODS: Totally 1542 patients from four independent cohorts were enrolled, including our localized Zhongshan hospital (ZSHS) cohort and Zhongshan hospital metastatic RCC (ZSHS-mRCC) cohort, The Cancer Genome Atlas (TCGA) cohort and CheckMate cohort...
April 12, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38605349/esco2-s-oncogenic-role-in-human-tumors-a-pan-cancer-analysis-and-experimental-validation
#15
JOURNAL ARTICLE
Yue Huang, Dapeng Chen, Yi Bai, Yamin Zhang, Zhiwen Zheng, Qingfeng Fu, Bocun Yi, Yuchen Jiang, Zhihong Zhang, Jianqiang Zhu
PURPOSE: Establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2) is involved in the mitotic S-phase adhesins acetylation and is responsible for bridging two sister chromatids. However, present ESCO2 cancer research is limited to a few cancers. No systematic pan-cancer analysis has been conducted to investigate its role in diagnosis, prognosis, and effector function. METHODS: We thoroughly examined the ESCO2 carcinogenesis in pan-cancer by combining public databases such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), UALCAN and Tumor Immune Single-cell Hub (TISCH)...
April 11, 2024: BMC Cancer
https://read.qxmd.com/read/38605343/cellular-senescence-and-metabolic-reprogramming-model-based-on-bulk-single-cell-rna-sequencing-reveals-ptger4-as-a-therapeutic-target-for-ccrcc
#16
JOURNAL ARTICLE
Lijie Zhou, Youmiao Zeng, Yuanhao Liu, Kaixuan Du, Yongbo Luo, Yiheng Dai, Wenbang Pan, Lailai Zhang, Lei Zhang, Fengyan Tian, Chaohui Gu
Clear cell renal cell carcinoma (ccRCC) is the prevailing histological subtype of renal cell carcinoma and has unique metabolic reprogramming during its occurrence and development. Cell senescence is one of the newly identified tumor characteristics. However, there is a dearth of methodical and all-encompassing investigations regarding the correlation between the broad-ranging alterations in metabolic processes associated with aging and ccRCC. We utilized a range of analytical methodologies, such as protein‒protein interaction network analysis and least absolute shrinkage and selection operator (LASSO) regression analysis, to form and validate a risk score model known as the senescence-metabolism-related risk model (SeMRM)...
April 11, 2024: BMC Cancer
https://read.qxmd.com/read/38600002/pro-cancer-role-of-cd276-as-a-novel-biomarker-for-clear-cell-renal-cell-carcinoma
#17
JOURNAL ARTICLE
Zhi-Yu Zhang, Jian-Hao Xu, Jiang-Lei Zhang, Yu-Xin Lin, Jun Ou-Yang
OBJECTIVE: Renal cell carcinoma (RCC) is a common malignant tumor with a high incidence in males and the elderly, and clear cell RCC (ccRCC) is the most common RCC subtype. ccRCC is highly metastatic with a poor prognosis. Therefore, it is crucial to obtain a detailed understanding of the molecular mechanism of ccRCC and to identify suitable biomarkers to realize early diagnosis and improve prognosis. METHODS: We analyzed data from the Cancer Genome Atlas, investigated the overall differential expression of CD276 in ccRCC, and evaluated the influence of CD276 on patient survival and prognosis...
April 9, 2024: Urologic Oncology
https://read.qxmd.com/read/38599101/machine-learning-based-integration-develops-a-stress-response-stated-t-cell-tstr-related-score-for-predicting-outcomes-in-clear-cell-renal-cell-carcinoma
#18
JOURNAL ARTICLE
Shuai Yang, Zhaodong Han, Zeheng Tan, Zhenjie Wu, Jianheng Ye, Shanghua Cai, Yuanfa Feng, Huichan He, Biyan Wen, Xuejin Zhu, Yongkang Ye, Huiting Huang, Sheng Wang, Weide Zhong, Yulin Deng
BACKGROUND: Establishment of a reliable prognostic model and identification of novel biomarkers are urgently needed to develop precise therapy strategies for clear cell renal cell carcinoma (ccRCC). Stress response stated T cells (Tstr) are a new T-cell subtype, which are related to poor disease stage and immunotherapy response in various cancers. METHODS: 10 machine-learning algorithms and their combinations were applied in this work. A stable Tstr-related score (TCs) was constructed to predict the outcomes and PD-1 blockade treatment response in ccRCC patients...
April 9, 2024: International Immunopharmacology
https://read.qxmd.com/read/38599011/cholesterol-accumulation-in-ccrcc-the-role-of-ccrcc-initiating-vhl-hif%C3%AE-pathway
#19
JOURNAL ARTICLE
M Aiman Mohtar, Siti Nur Hasanah Mohd Yusuf, Saiful Effendi Syafruddin
No abstract text is available yet for this article.
April 9, 2024: EBioMedicine
https://read.qxmd.com/read/38595297/clinicopathologic-and-molecular-characterization-of-xanthomatous-giant-cell-renal-cell-carcinomas-further-support-for-a-close-morphologic-spectrum-to-eosinophilic-solid-and-cystic-renal-cell-carcinomas
#20
JOURNAL ARTICLE
Yuemei Xu, Xue Zhang, Qiuyuan Xia, Yuning Zhou, Xiaotong Wang, Ru Fang, Ya Wang, Qi Tong, Jieyu Chen, Jiong Shi, Yao Fu, Qiu Rao
A recent study described a rare subtype of tuberous sclerosis complex (TSC)-mutated renal cell carcinoma primarily characterized by Xanthomatous giant cell morphology. Only 2 cases in young individuals have been reported so far, making the correct diagnosis challenging from a pathological perspective. It remains unknown whether this tumor represents an independent subtype or belongs to other TSC-mutated tumors. We conducted a clinicopathologic evaluation and immunohistochemical profiling of 5 cases of Xanthomatous Giant Cell Renal Cell Carcinoma (XGC RCC) with confirmed TSC2 mutations through targeted DNA sequencing...
April 9, 2024: American Journal of Surgical Pathology
keyword
keyword
42598
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.